Study Finds Proton and Photon Radiation Treatments Equally Effective for Breast Cancer Patients’ Quality of Life

A large-scale phase III clinical trial comparing proton therapy and traditional photon radiation for breast cancer has demonstrated that both treatment methods maintain comparable levels of patient-reported quality of life. The RadComp trial, involving over 1,200 participants across 32 centers in the United States, aimed to determine whether proton therapy could offer advantages in reducing side effects while effectively controlling cancer. Results showed that patients treated with either approach reported high satisfaction and similar outcomes in physical, emotional, and cosmetic aspects. Notably, patients receiving proton therapy were more likely to recommend or opt for the treatment again, possibly influenced by perceptions of the treatment’s modernity or cost. While some patients in the proton group reported fewer symptoms of shortness of breath, this difference was not statistically significant after rigorous analysis. These findings provide reassurance that both options are viable for breast cancer treatment, with future studies set to evaluate long-term cancer control and cardiac outcomes. Breast cancer remains the most common cancer diagnosis in the U.S., often requiring surgery followed by radiation to prevent recurrence. The choice between photon and proton therapy has been debated due to cost and availability concerns, but this trial substantiates their comparable efficacy in preserving quality of life.